Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | QPCT | Q16769 | 10/20 | 0.42 |
| ▸ | IRAK4 | Q9NWZ3 | 9/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12344414 | 0.91 | QPCT (0.42) | QPCT | |
| SCHEMBL12299666 | 0.87 | QPCT (0.42) | QPCT | |
| SCHEMBL12300584 | 0.87 | QPCT (0.40) | QPCT | |
| SCHEMBL13643286 | 0.84 | QPCT (0.53) | QPCT | |
| SCHEMBL13643310 | 0.84 | QPCT (0.51) | QPCT | |
| SCHEMBL12344548 | 0.81 | QPCT (0.52) | QPCT | |
| SCHEMBL2379750 | 0.80 | QPCT (0.50) | QPCT | |
| SCHEMBL12299659 | 0.80 | QPCT (0.42) | QPCT | |
| SCHEMBL12301392 | 0.77 | QPCT (0.39) | QPCT | |
| SCHEMBL2381781 | 0.77 | QPCT (0.51) | QPCT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120283259-A1 | NOVEL INHIBITORS | PROBIODRUG AG (DE) | 2012-11-08 | — | — | US | disclosed |
| US-8269019-B2 | Inhibitors | PROBIODRUG AG (DE) | 2012-09-18 | — | — | US | disclosed |
| US-20110224254-A1 | NOVEL INHIBITORS | PROBIODRUG AG (DE) | 2011-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224254-A1 | NOVEL INHIBITORS | GLUL, QPCT, GLS | QPCT 2/4885IRAK4 3403/4885CYP3A4 1974/4885 |
| US-20120283259-A1 | NOVEL INHIBITORS | GLUL, QPCT, GLS | QPCT 2/4885IRAK4 3403/4885CYP3A4 1974/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.